Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)
Funding Amount
Not stated
Deadline
Forecast — dates not yet posted
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Tribal organizations
- Public colleges & universities
- Private colleges & universities
- Tribal governments
- Small businesses
- State governments
- Public & Indian housing authorities
- School districts
Overview
The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine. The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe) , is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration. Areas of interest for ExTReMe could include, but are not limited to: direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies); designer EVs (personalized to the individual patient’s needs). Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: FOR-TR-27-002
- Instrument: cooperative_agreement
Focus Areas & Funding Uses
Fields of Work
- Science research
- Healthcare
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe). Now let's win it.